2023.09.05
I-Mab Announces Upcoming Participation at September Conferences
I-Mab announced participation in investor conferences in September 2023.
2023.09.05
I-Mab announced participation in investor conferences in September 2023.
2023.08.17
The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.
2023.08.08
I-Mab will host an investor call to report interim earnings on Aug 17.
2023.07.05
The Company published a manuscript in JITC demonstrating mechanism of givastomig in the treatment of CLDN18.2-expressing tumors through the targeted activation of 4-1BB mediated T cells.
2023.06.22
Mr. Raj Kannan joins the Company as Chief Executive Officer and a member of the board of directors.
2023.05.26
The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.
2023.04.26
The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.
2023.04.25
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.
2023.04.24
The first patient in a Phase 3 registrational trial in China for patients with HR-MDS has been dosed with lemzoparlimab in combination with AZA.
2023.03.31
The Company today announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.